The Role of Resolvins, Protectins and Marensins in Non-Alcoholic Fatty Liver Disease (NAFLD)

被引：16
|
作者：
Maciejewska-Markiewicz, Dominika [1 ]
Stachowska, Ewa [1 ]
Hawrylkowicz, Viktoria [1 ]
Stachowska, Laura [1 ]
Prowans, Piotr [2 ]
机构：
[1] Pomeranian Med Univ, Dept Human Nutr & Metabol, PL-70204 Szczecin, Poland
[2] Pomeranian Med Univ, Clin Plast Endocrine & Gen Surg, PL-72009 Police, Poland
来源：
BIOMOLECULES | 2021年 / 11卷 / 07期
关键词：
NAFLD; n-3; PUFA; resolvins; protectins; marensins; LEUKOTRIENE A(4) HYDROLASE; ANTIINFLAMMATORY ACTIONS; RESOLUTION; MEDIATORS; ACID; D1; INFLAMMATION; STEATOSIS; OMEGA-3-FATTY-ACIDS; ACCUMULATION;
D O I：
10.3390/biom11070937
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Increased triacylglycerols' (TAG) synthesis, insulin resistance, and prolonged liver lipid storage might lead to the development of non-alcoholic fatty liver disease (NAFLD). Global prevalence of NAFLD has been estimated to be around 25%, with gradual elevation of this ratio along with the increased content of adipose tissue in a body. The initial stages of NAFLD may be reversible, but the exposition to pathological factors should be limited. As dietary factors greatly influence various disease development, scientists try to find dietary components, helping to alleviate the steatosis. These components include n-3 polyunsaturated (PUFA) fatty acids, especially eicosapentaenoic acid (EPA) and docosahexaenoic acids (DHA). This review focused on the role of resolvins, protectins and merensins in NAFLD.
引用
收藏
页数：9
相关论文
共 50 条
  • [1] Protective Role of Coffee in Non-alcoholic Fatty Liver Disease (NAFLD)
    Catalano, Daniela
    Martines, Giuseppe Fabio
    Tonzuso, Antonia
    Pirri, Clara
    Trovato, Francesca M.
    Trovato, Guglielmo M.
    DIGESTIVE DISEASES AND SCIENCES, 2010, 55 (11) : 3200 - 3206
  • [2] Protective Role of Coffee in Non-alcoholic Fatty Liver Disease (NAFLD)
    Daniela Catalano
    Giuseppe Fabio Martines
    Antonia Tonzuso
    Clara Pirri
    Francesca M. Trovato
    Guglielmo M. Trovato
    Digestive Diseases and Sciences, 2010, 55 : 3200 - 3206
  • [3] Diagnosis of non-alcoholic fatty liver disease (NAFLD)
    Hannele Yki-Järvinen
    Diabetologia, 2016, 59 : 1104 - 1111
  • [4] Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention
    Tacke, Frank
    Weiskirchen, Ralf
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (08)
  • [5] Diagnosis of non-alcoholic fatty liver disease (NAFLD)
    Yki-Jarvinen, Hannele
    DIABETOLOGIA, 2016, 59 (06) : 1104 - 1111
  • [6] Non-alcoholic fatty liver disease (NAFLD) in children
    Roberts, EA
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2005, 10 : 2306 - 2318
  • [7] Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in HIV
    Jürgen Kurt Rockstroh
    Current HIV/AIDS Reports, 2017, 14 : 47 - 53
  • [8] Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in HIV
    Rockstroh, Juergen Kurt
    CURRENT HIV/AIDS REPORTS, 2017, 14 (02) : 47 - 53
  • [9] Non-alcoholic fatty liver disease (NAFLD) models in drug discovery
    Cole, Banumathi K.
    Feaver, Ryan E.
    Wamhoff, Brian R.
    Dash, Ajit
    EXPERT OPINION ON DRUG DISCOVERY, 2018, 13 (02) : 193 - 205
  • [10] The Role of Non-Alcoholic Fatty Liver Disease in Cardiovascular Disease
    Perseghin, Gianluca
    DIGESTIVE DISEASES, 2010, 28 (01) : 210 - 213
12345